Monashee Investment Management LLC Makes New Investment in ImageneBio, Inc. $IMA

Monashee Investment Management LLC purchased a new position in shares of ImageneBio, Inc. (NASDAQ:IMA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 91,621 shares of the company’s stock, valued at approximately $632,000. Monashee Investment Management LLC owned 0.82% of ImageneBio at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Atlas Venture Life Science Advisors LLC purchased a new stake in ImageneBio during the 3rd quarter worth about $3,079,000. BML Capital Management LLC purchased a new stake in ImageneBio during the 3rd quarter worth about $1,487,000. Blue Owl Capital Holdings LP purchased a new stake in ImageneBio during the 3rd quarter worth about $4,409,000. Deep Track Capital LP purchased a new position in shares of ImageneBio in the 3rd quarter valued at about $7,160,000. Finally, Vanguard Group Inc. purchased a new position in shares of ImageneBio in the 3rd quarter valued at about $1,902,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analyst Ratings Changes

IMA has been the topic of a number of recent analyst reports. Wall Street Zen downgraded ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Wedbush reiterated an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, ImageneBio has an average rating of “Hold” and an average price target of $26.50.

ImageneBio Stock Performance

IMA opened at $5.71 on Friday. ImageneBio, Inc. has a one year low of $3.94 and a one year high of $18.00. The company has a market cap of $60.83 million, a P/E ratio of -0.99 and a beta of 0.72. The business’s 50-day simple moving average is $5.58 and its 200-day simple moving average is $6.17.

ImageneBio (NASDAQ:IMA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25). As a group, analysts predict that ImageneBio, Inc. will post -3.66 earnings per share for the current fiscal year.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.